Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Thallion Pharmaceuticals Inc V.TLN

TSXV:TLN - Post Discussion

Thallion Pharmaceuticals Inc > Further comment
View:
Post by dreamer05 on Jun 18, 2013 9:56pm

Further comment

Why would anyone sell this tock @18 cents when the cash position alone 0f TLN worths more than 23 cents, plus the possible sucess of the Shigamab drug which is phase 2 completed.  Somehow in the deal they mention about the 5% profits goes to the cvr. To me , the Shigmab is 100 % owned by TLN why 95 % profits goes to Bellus.Can anyone explaain to me. If you count all the stuffs TLN still has this stock vaues at least 50  share. Why would any dummy CEO would sell this company for 6.5 miiions to Bellus.  I need someone out there explain to me please, or comment on the deal. Are we shareholders are idiots or what?
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities